CR2 and B-cell non-Hodgkin lymphoma: Furthermore, since CD21 is only expressed in approximately two-third of B-cell lymphomas and only at low levels in half of those (Table I), our results may even be of clinical importance in selecting appropriate patients for anti-CD19 ADC therapy.